Abstract：Objective To analyze the relationship between serum vitamin D (VitD) and folic acid (FA) levels and sensitivity of neoadjuvant chemotherapy in patients with triple-negative breast cancer(TNBC). Methods After receiving neoadjuvant chemotherapy, 235 TNBC patientspathologically diagnosed withresidual cancer were selected as the observation group, while 235 TNBC patients diagnosed with pathological complete response served as the control group. The patients’ general characteristics, tumor size, TNM staging, lymph node, Ki-67 expression and basal marker condition were retrospectively collected, and the levels of serum VitD and FA were detected by enzyme-linked immunosorbent assay. The relationship between serum VitD and FA levels and sensitivity of neoadjuvant chemotherapy in all the TNBC patients after neoadjuvant chemotherapy was analyzed by logistic regression and receiver operating characteristic (ROC) curve. Results Single factor analysis indicated that serum VitD and FA levels were lower in the observation group than in the control group, showing statistically significant differences (both P<0.05). The proportions of patients with a tumor size T3/4, Ki-67 low-expession, positive basal marker and having a decreasing trend in serum VitD and FA levels in the observation group were significantly higher than those of the control group, with statistically significant differences(all P<0.05). However, no statistically significant differences were found in age, TNM staging and lymph node status between the two groups (all P>0.05). Logistic regression analysis showed that a tumor size T3/4 (OR=4.122, 95%CI:2.768-7.502), Ki-67 low-expession (OR=4.193, 95%CI:1.967-8.880), positive basal marker (OR=3.459, 95%CI:1.884-80.30) and having a decreasing trend in serum levels of VitD (OR=2.689, 95%CI:1.656-4.306) and FA(OR=2.005, 95%CI:1.470-3.436) were associated with poor effects of neoadjuvant chemotherapy. ROC analysis revealed that the prognostic sensitivity and specificity of poor effects of neoadjuvant chemotherapy separately predicted by serum VitD and FA were 0.782 and 0.899, 0.775 and 0.862 respectively, while the sensitivity and specificity predicted by VitD in combination with FA were 0.856 and 0.908 respectively. Conclusions The decrease of serum VitD and FA levels can increase the risk of poor response to neoadjuvant chemotherapy in patients with TNBC, and both can be used as the effective indexes for evaluating the sensitivity of neoadjuvant chemotherapy.
王一,廖宏伟,宋扬. 血清VitD、FA水平与三阴乳腺癌患者新辅助化疗敏感性关系[J]. 实用预防医学, 2018, 25(4): 405-408.
WANG Yi, LIAO Hong-wei, SONG Yang. Relationship between serum vitamin D, folic acid and the sensitivity of neoadjuvant chemotherapy in patients with triple-negative breast cancer. , 2018, 25(4): 405-408.
2018, Vol. 25 
